ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2022 Annual General Meeting held on May 18, 2022
May 19 2022 - 7:00AM
Ad hoc announcement pursuant to Art. 53 LR of the
SIX Swiss Exchange
Geneva,
Switzerland – May
19,
2022 – ObsEva
SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company
developing and commercializing novel therapies for women’s health,
today announced that shareholders approved all Board proposals at
its 2022 Annual General Meeting held on May 18, 2022.
The approved items are as
follows:
-
Shareholders approved the Annual Report, the Statutory Financial
Statements and the Consolidated Financial Statements for Fiscal
Year 2021
-
Shareholders granted discharge to the Members of the Board of
Directors and to the Executive Committee for year 2021
-
Shareholders approved the proposed appropriation of the Financial
Results for year 2021
-
Shareholders approved the proposed elections to the Board of
Directors and election of the Chairperson of the Board of
Directors
-
Shareholders approved the proposed elections to the Compensation
Committee
-
Shareholders approved the re-election of PricewaterhouseCoopers SA
as ObsEva SA’s Auditors and Independent Registered Public
Accounting Firm
-
Shareholders approved the re-election of Perréard de Boccard SA as
Independent Representative
-
Shareholders approved the proposed compensation of the Board of
Directors and the Executive Committee
-
Shareholders approved the proposed increase of ObsEva SA’s
Authorized Share Capital
-
Shareholders approved the proposed increase of ObsEva SA’s
Conditional Share Capital for Financing Purposes
-
Shareholders approved the proposed increase of ObsEva SA’s
Conditional Share Capital for Equity Plans
-
Shareholders approved the proposed change to ObsEva SA’s Equity
Incentive Plan
-
Shareholders approved the Issuance of Conversion Shares and Warrant
Shares under Securities Purchase Agreement
For a detailed agenda, including items submitted
to shareholders’ vote and related proposals of the Board of
Directors, please refer to the full invitation, which may be found
in the Investors / General Meetings section of the company’s
website www.ObsEva.com.
To access the general meetings section of the
Company’s website, please click here.
To access the AGM 2022 section of the general
meetings section directly, please click here.
To access the full invitation to the AGM 2022
directly, please click here.
About ObsEvaObsEva is a
biopharmaceutical company developing and commercializing novel
therapies to improve women’s health. Through strategic in-licensing
and disciplined drug development, ObsEva has established a
late-stage clinical pipeline with development programs focused on
new therapies for the treatment of uterine fibroids, endometriosis,
and preterm labor. ObsEva is listed on the Nasdaq Global Select
Market and is traded under the ticker symbol “OBSV” and on the SIX
Swiss Exchange where it is traded under the ticker symbol “OBSN”.
For more information, please visit www.ObsEva.com.
For further information, please contact:
CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact:
Katja Bührer
Katja.buhrer@obseva.com
+1 (917) 969-3438
ObsEva (NASDAQ:OBSV)
Historical Stock Chart
From Mar 2024 to Apr 2024
ObsEva (NASDAQ:OBSV)
Historical Stock Chart
From Apr 2023 to Apr 2024